Somagenics
has funded its early, high-risk studies to develop
and validate the technology through 15 government
grants and contracts totaling about $4.5 million
over the past four years, mostly through the Small
Business Innovation Research Program of the US National
Institutes of Health (NIH), the Defense Advanced
Research Projects Agency (DARPA) and the US National
Science Foundation (NSF).